

### REMARKS

The present paper is submitted concurrently with a Rule 53(b) continuation application of Serial No. 08/714,175.

The present paper amends the specification along the lines of the amendments to the specification of the parent application.

The amendment cancels without prejudice original claims 1-11 and adds new claims 12-18. Claims 12-18 correspond to claims 12-18 in the parent application, except claim 12 has been further amended in response to the Advisory Action dated December 5, 2001. Specifically, claim 12 is amended to clarify that the TRAP antigen is a thrombospondin related anonymous protein (TRAP) malarial antigen. This is supported in the specification for example at page 1, lines 35-36 and page 2, line 2. Claim 12 is further amended to ensure that the meanings of the acronyms "HLA" and "CTLs" are clear.

In view of these amendments, it is clear what antigens are encompassed by this term.

It is furthermore considered to be clear that the TRAP is a single protein as defined by Robson et al. See the specification at page 1, lines 35-36 and page 15, line 10. Hence there is no new matter or written description issue raised.


Although non-elected, claim 18 is again presented and has been amended to correspond to pending claim 12. Accordingly, upon an allowance of claims 12-17, claim 18 should be rejoined under PTO rules.

Finally there is submitted therewith a substitute Sequence Listing in paper and computer readable form. The paper and computer readable copies are identical. No new matter is added.

Favorable action and allowance is solicited.

Respectfully submitted,

Adrian Vivian Sinton HILL et al.

By   
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
January 11, 2002

10043202-01102